| 1. |
Kato K, Epigenetics in lymphocyte and lymphoma: EZH2 as an easy-to-access therapeutic target? , 消化器内視鏡, 2022.12. |
| 2. |
Tsukasaki K, Marçais A, Nasr R, Kato K, Fukuda T, Hermine O, Bazarbachi A. , Diagnostic Approaches and Established Treatments for Adult T Cell Leukemia Lymphoma., Front Microbiol. , doi:10.3389/fmicb.2020.01207, 2020;11:1207. , 2020.06. |
| 3. |
Ogata M, Uchida N, Fukuda T, Ikegame K, Kamimura T, Onizuka M, Kato K, Kobayashi H, Sasahara Y, Sawa M, Sawada A, Hasegawa D, Masuko M, Miyamoto T, Okamoto S. , Clinical practice recommendations for the diagnosis and management of human herpesvirus-6B encephalitis after allogeneic hematopoietic stem cell transplantation: the Japan Society for Hematopoietic Cell Transplantation. , Bone Marrow Transplant. , 2020; 55: 1004-1013., 2020.03. |
| 4. |
Kato K, Takeuchi A, Akashi K, Eto M. , Cyclophosphamide-Induced Tolerance in Allogeneic Transplantation: From Basic Studies to Clinical Application. , Front Immunol. , doi: 10.3389/fimmu.2019.03138., 2020 Jan 31;10:3138. eCollection 2019. , 2020.01. |
| 5. |
Fuji S, Kato K, Nakano N, Ishida T, Ishitsuka K, Choi I, Matsuoka KI, Utsunomiya A, Pre- and posttransplant use of mogamulizumab in patients with aggressive adult T-cell leukemia-lymphoma: A statement from key opinion leaders in Japan, Adv Cell Gene Ther., Adv Cell Gene Ther. 1: e5, 2018, 2018.06. |
| 6. |
Takeuchi A, Kato K, Akashi K, Eto M. , Cyclophosphamide-induced tolerance in kidney transplantation avoids long-term immunosuppressive therapy.
, Int J Urol. , Int J Urol. 2018; 25: 112-120., 2018.02. |
| 7. |
Kato K, Akashi K, Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma., Viruses, 2015.12. |
| 8. |
Kato K, Khaled Y, Mineishi S. , Reduced-intensity stem cell transplantation for hematological malignancies: Current status and the future. , Current Stem Cell Research & Therapy. 2007; 2: 149-162., 2007.04. |
